News

A phase 2 trial met its primary endpoint, showing NBI-1117568, the first M4 selective agonist, is effective and safe at treating adult schizophrenia.

These data reaffirm NB-UVB phototherapy’s use in treating patients with atopic dermatitis and psoriasis, suggesting improvement in patient-reported outcome measures.

A new study found patients with chronic pruritus of unknown origin have reductions in 15 metabolites compared to healthy controls.

Brolucizumab achieved non-inferiority in mean BCVA change to aflibercept in eyes with nAMD but demonstrated a higher incidence of IOI at 2 years.

This analysis was designed to examine ChatGPT’s accuracy in diagnosing dermatologic conditions among those with and without skin of color.

Patients with psoriasis show greater H. pylori infection rates, but no link to psoriasis severity, suggesting further research is needed on this potential connection.

Michigan Medicine and U-M research finds a bidirectional link between mental health disorders and chronic diabetes complications, urging comprehensive screenings.

A retrospective study in Japan identified 3 cases of non-infectious IOI associated with retinal vasculitis after aflibercept 8 mg treatment.

During this segment of a recent Lungcast, Mora and Sadeameli speak about 2 key topics: vaping and e-cigarette use among children as well as vaccinations and related misinformation.

There were no significant differences in the overall incidence of AEs and serious AEs.

FDA expands Omnipod 5 AID system for type 2 diabetes, marking the first AID system approved for both type 1 and type 2 diabetes management.

A study found that women with trauma history have reduced liver transplant access compared to men, with gender disparities not driven by psychiatric symptoms.

A new study found hepatitis C virus reinfections may occur within 24 weeks of sustained virologic response after injecting drugs.

Heat-related mortality rates in the US notably grew between 1999 and 2023, particularly since 2016.

Qazi discusses a review of considerations for GLP-1 RA use in the context of endoscopic procedures due to their impact on gastric emptying and bowel motility.

With the growing popularity of GLP-1 receptor agonists, understanding their impact on gastric emptying, bowel motility, and potential implications for endoscopy is essential.

Qazi reviews findings from a study exploring the safety of endoscopic retrograde cholangiopancreatography in the early versus late post-transplant period.

Patients who underwent ERCP ≤ 30 days post-transplant had greater rates of early post-procedure bleeding but similar rates of technical and clinical success compared to late ERCP.

Qazi reviews findings from a study exploring potential causes of seronegative villous atrophy, emphasizing the importance of maintaining a broad differential in diagnosis.

Findings suggest a heterogeneous makeup of seronegative enteropathies, presenting difficulty in diagnosing patients with villous atrophy and negative celiac serologic testing.

Dexcom's Stelo, the first OTC glucose sensor, launches in the US on August 26, 2024, offering 15-day wear and HSA/FSA eligibility for as low as $89.99 per 2-pack.

Moderate to severe anemia was linked to an increase in cardiac arrest or stroke compared with normal hemoglobin levels in critically ill COVID-19 patients.

Findings support the use of liver grafts from donation after circulatory death and HCV-positive donors, citing comparable 1-year patient and graft survival.

Nocturnal hypoxia may represent an additional modifiable risk factor for AMD, particularly its neovascular form.

This analysis evaluated the long-term follow-up and risks linked to the self-reported penicillin allergy persistence after a successful oral penicillin challenge and allergy label removal.

A new study revealed children who go from normal weight to overweight have a greater risk of atopic dermatitis than obese children who maintain their weight.

Kumar explains what is known about the use of PPAR agonists in primary biliary cholangitis and the significance of the recent FDA accelerated approvals of elafibranor and seladelpar.

Intensive lipid-lowering treatment regimens were linked to a notable reduction in three-point MACE risk and ACS recurrence versus background statin therapy.